BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 23457546)

  • 1. EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells.
    Rommer A; Steinmetz B; Herbst F; Hackl H; Heffeter P; Heilos D; Filipits M; Steinleitner K; Hemmati S; Herbacek I; Schwarzinger I; Hartl K; Rondou P; Glimm H; Karakaya K; Krämer A; Berger W; Wieser R
    PLoS One; 2013; 8(2):e56308. PubMed ID: 23457546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia.
    Fisser MC; Rommer A; Steinleitner K; Heller G; Herbst F; Wiese M; Glimm H; Sill H; Wieser R
    Mol Carcinog; 2015 Dec; 54(12):1815-9. PubMed ID: 25491945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.
    Steinmetz B; Hackl H; Slabáková E; Schwarzinger I; Smějová M; Spittler A; Arbesu I; Shehata M; Souček K; Wieser R
    Cell Cycle; 2014; 13(18):2931-43. PubMed ID: 25486480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
    Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
    Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EVI1 promotes tumor growth via transcriptional repression of MS4A3.
    Heller G; Rommer A; Steinleitner K; Etzler J; Hackl H; Heffeter P; Tomasich E; Filipits M; Steinmetz B; Topakian T; Klingenbrunner S; Ziegler B; Spittler A; Zöchbauer-Müller S; Berger W; Wieser R
    J Hematol Oncol; 2015 Mar; 8():28. PubMed ID: 25886616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes.
    Konrad TA; Karger A; Hackl H; Schwarzinger I; Herbacek I; Wieser R
    J Leukoc Biol; 2009 Oct; 86(4):813-22. PubMed ID: 19605700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid.
    Verhagen HJ; Smit MA; Rutten A; Denkers F; Poddighe PJ; Merle PA; Ossenkoppele GJ; Smit L
    Blood; 2016 Jan; 127(4):458-63. PubMed ID: 26582376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The increased expression of integrin α6 (ITGA6) enhances drug resistance in EVI1(high) leukemia.
    Yamakawa N; Kaneda K; Saito Y; Ichihara E; Morishita K
    PLoS One; 2012; 7(1):e30706. PubMed ID: 22295105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiopoietin1 contributes to the maintenance of cell quiescence in EVI1(high) leukemia cells.
    Ichihara E; Kaneda K; Saito Y; Yamakawa N; Morishita K
    Biochem Biophys Res Commun; 2011 Dec; 416(3-4):239-45. PubMed ID: 22033412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737.
    Shimada K; Tomita A; Minami Y; Abe A; Hind CK; Kiyoi H; Cragg MS; Naoe T
    Exp Hematol; 2012 Sep; 40(9):724-737.e2. PubMed ID: 22634393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ecotropic viral integration site 1, a novel oncogene in prostate cancer.
    Queisser A; Hagedorn S; Wang H; Schaefer T; Konantz M; Alavi S; Deng M; Vogel W; von Mässenhausen A; Kristiansen G; Duensing S; Kirfel J; Lengerke C; Perner S
    Oncogene; 2017 Mar; 36(11):1573-1584. PubMed ID: 27617580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2.
    Gómez-Benito M; Conchillo A; García MA; Vázquez I; Maicas M; Vicente C; Cristobal I; Marcotegui N; García-Ortí L; Bandrés E; Calasanz MJ; Alonso MM; Odero MD
    Br J Cancer; 2010 Oct; 103(8):1292-6. PubMed ID: 20842122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A murine model of acute myeloid leukemia with Evi1 overexpression and autocrine stimulation by an intracellular form of GM-CSF in DA-3 cells.
    Cardona ME; Simonson OE; Oprea II; Moreno PM; Silva-Lara MF; Mohamed AJ; Christensson B; Gahrton G; Dilber MS; Smith CI; Arteaga HJ
    Leuk Lymphoma; 2016; 57(1):183-92. PubMed ID: 25907616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.
    Lugthart S; Figueroa ME; Bindels E; Skrabanek L; Valk PJ; Li Y; Meyer S; Erpelinck-Verschueren C; Greally J; Löwenberg B; Melnick A; Delwel R
    Blood; 2011 Jan; 117(1):234-41. PubMed ID: 20855866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment.
    Masamoto Y; Chiba A; Mizuno H; Hino T; Hayashida H; Sato T; Bando M; Shirahige K; Kurokawa M
    Blood Adv; 2023 Apr; 7(8):1577-1593. PubMed ID: 36269819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.
    Glass C; Wuertzer C; Cui X; Bi Y; Davuluri R; Xiao YY; Wilson M; Owens K; Zhang Y; Perkins A
    PLoS One; 2013; 8(6):e67134. PubMed ID: 23826213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The shortest isoform of C/EBPβ, liver inhibitory protein (LIP), collaborates with Evi1 to induce AML in a mouse BMT model.
    Watanabe-Okochi N; Yoshimi A; Sato T; Ikeda T; Kumano K; Taoka K; Satoh Y; Shinohara A; Tsuruta T; Masuda A; Yokota H; Yatomi Y; Takahashi K; Kitaura J; Kitamura T; Kurokawa M
    Blood; 2013 May; 121(20):4142-55. PubMed ID: 23547050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.
    Huang MJ; Cheng YC; Liu CR; Lin S; Liu HE
    Exp Hematol; 2006 Nov; 34(11):1480-9. PubMed ID: 17046567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of hsa-miR-124 by EVI1 in cell lines and patients with acute myeloid leukemia.
    Vázquez I; Maicas M; Marcotegui N; Conchillo A; Guruceaga E; Roman-Gomez J; Calasanz MJ; Agirre X; Prosper F; Odero MD
    Proc Natl Acad Sci U S A; 2010 Nov; 107(44):E167-8; author reply E169-70. PubMed ID: 20930122
    [No Abstract]   [Full Text] [Related]  

  • 20. All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia.
    Nguyen CH; Bauer K; Hackl H; Schlerka A; Koller E; Hladik A; Stoiber D; Zuber J; Staber PB; Hoelbl-Kovacic A; Purton LE; Grebien F; Wieser R
    Cell Death Dis; 2019 Dec; 10(12):944. PubMed ID: 31822659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.